Biogen eyes potential acquisitions – Stat News By Reuters

© Reuters. FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder/File Photo

(Reuters) – Biogen Inc (NASDAQ:) is working with investment bank Goldman Sachs (NYSE:) to find potential targets for acquisitions, Stat News reported on Thursday, citing an unnamed source.

The report said the company’s board had warmed to the idea of acquisitions amid the turmoil surrounding its controversial Alzheimer’s drug Aduhelm.

Biogen did not immediately reply to a Reuters request for comment on the report.

On Tuesday, the U.S. Centers for Medicaid and Medicare Services (CMS) said it would cover Aduhelm, and similar treatments, only for patients enrolled in approved clinical trials, threatening sales of the drug.

In a conference call with analysts on Thursday, Biogen Chief Executive Officer Michel Vounatsos said the management was engaging with the board on “tactical, short-term measures, but also strategic options”.

Vounatsos was replying to a query on whether the company would consider any strategic options to protect shareholder value, especially in light of the Aduhelm controversy.

Aduhelm was approved by the U.S. Food and Drug Administration in June despite a vote by the agency’s outside advisers that the treatment’s clinical benefits had not been proven.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button